Inhaled nitric oxide has been approved by FDA for treatment of hypoxic respiratory failure in term and near-term neonates. The safety of withdrawing NO in patients who fail to respond is a major concern.
INTRODUCTION
Multiple studies have described the benefits of nitric oxide in increasing oxygenation in neonates with pulmonary hypertension. [1] [2] [3] [4] [5] Since FDA approval of inhaled nitric oxide for treatment of hypoxic respiratory failure, more neonatal intensive care units have added this treatment to their therapeutic armamentarium. The safety of its use in centers without the facility for extracorporeal membrane oxygenation (ECMO) has been questioned, in part because of case reports describing rebound pulmonary hypertension and life-threatening hypoxemia following its discontinuation. 6, 7 In an attempt to further understand the safety of withdrawing NO in nonresponders following a brief exposure, we performed a retrospective chart review of data from Packard Children's Hospital patients enrolled in the Neonatal Nitric Oxide Study (NINOS) trial.
METHODS
As per existing NINOS protocol, subjects who met criteria received study gas at an initial dose of 20 ppm. 1 If there was less than a 20 mmHg increase in PaO 2 after 30 minutes, study gas was stopped for 15 minutes and a blood gas was obtained. The dose was then increased to 80 ppm. The open label protocol allowed for an increase in NO from 20 to 40 ppm for an increase in PaO 2 of less than 20 mmHg. Blood gases were obtained 30 minutes after initiating study gas and 30 minutes after discontinuing study gas. An unpaired Student's t-test was used to compare the placebo group to the 20 ppm. (The high-dose group was excluded from this calculation, as they had more than one exposure to NO.) A paired Student's t-test was used to compare pre-and postvalues for each group. Statistical significance was set at 0.05.
RESULTS
The charts of 97 patients having received inhaled NO and 13 patients having received placebo from 1995 to 1999 within the NINOS trial guidelines were reviewed. After May 1996, qualifying patients were given open label NO.
A total of 38 patients were excluded: two had protocol deviations, eight patients expired while on NO and 28 went on ECMO while on NO. Of the remaining 72 subjects, 49 were responders and 23 were nonresponders. Of the 23 nonrespondents, 14 received NO as the study gas.
Gestational age for both groups ranged from 34 to 42 weeks. Diagnoses for both groups were similar (Table 1 ). All but one patient was ventilated with a high-frequency oscillatory ventilator (Sensor Medics, Yorba Linda, CA). In all, 71% of the responders received surfactant compared with 62% of the nonresponders.
Of the NO recipients, four received NO at 80 ppm; three failed, two went on to ECMO, one continued to be managed without NO. Four patients failed to respond at 40 ppm and went on to ECMO. Three patients failed at 20 ppm and went directly onto ECMO due to deteriorating clinical status. Nine patients receiving placebo were nonresponders; eight went onto ECMO, one expired.
Data from NO nonresponders were grouped based on NO dose. Data points for subjects receiving 40 and 80 ppm NO were pooled and labeled ''high-dose''. In all, 10 patients are included in the 20 ppm group and seven in the high-dose group.
The total number of patients who were nonresponders to NO was 14 (three patients received NO at both 20 and 80 ppm, two received 80 ppm initially under the open label protocol as per the attending physician's preference and two received 40 ppm initially).
Results are expressed as mean oxygenation index (OI) and standard deviation (SD). (OI ¼ mean airways pressure Â FIO 2 Â 100/PaO 2 ). Individual data points are shown in Figures  1 and 2 . For the high-dose group, the pre-NO OI was 49.9 (10.4), OI during NO was 52.7(20.4) and post-NO OI was 49.0 (21.0), p ¼ 0.55.
For the nonresponders at 20 ppm, the mean pre-NO OI was 41.7 (11.0), OI during NO was 38.6 (10.4) and post-NO OI was 34.3 (17.9), p ¼ 0.07. In the placebo group, pre-OI was 58.3 (16.2), OI during NO was 56.6 (13.2) and post-OI was 73.1 (19.0), p ¼ 0.03. ( Table 2 ). The percent change of oxygenation indices was calculated for each group (Table 3) . For both high-dose and 20 ppm nonresponder groups, there was no significant change from baseline after withdrawing NO for 30 minutes. The placebo group demonstrated a significant increase in OI from baseline (Table 4) .
DISCUSSION
This study demonstrated no significant increase in OI from baseline in pulmonary hypertensive patients with significant hypoxia who failed to respond to nitric oxide, following withdrawal of this therapy. A recent prospective, randomized, placebocontrolled study by Davidson et al. 6 showed a significant reduction in oxygenation following withdrawal of NO. There are several confounding factors in the design of the Davidson et al. study that may have affected the results. Firstly, patients having received surfactant or a high-frequency mode of ventilation were excluded from enrollment. Previous studies have shown that high-frequency ventilation augments the effect of inhaled nitric oxide in pulmonary hypertension patients. [8] [9] [10] High-frequency ventilation is considered by many to be superior to conventional ventilation in optimizing lung volume, particularly in parenchymal lung disease, which is frequently associated with PPHN. It is possible that the ''nonresponders'' in the study by Davidson et al. 8 study may have responded to NO had their ventilation been optimal. It is possible that the distribution of NO was limited only to alveoli recruited on conventional mechanical ventilation. Kinsella et al. 6 have shown enhanced response of PPHN patients to NO when HFOV was added to their therapy. Secondly, Davidson et al. 6 study also excluded patients having received surfactant. Secondary surfactant deficiency or inactivation may contribute to the progression of parenchymal disease. As NO reacts with oxygen, it forms reactive species that destroy surfactant. 11 Thirdly, patients in Davidson et al. 6 study who showed evidence of rebound hypertension had exposures to NO for several hours.
Refractory hypoxemia following cessation of NO is related to the downregulation of endogenous NO synthase. 12, 13 As such, this downregulation may be related to length of exposure. It is possible that other mechanisms may play a role in this phenomenon, although recent studies have shown that exogenous NO does not downregulate NO/cGMP pathways. 14 In fact, one study demonstrated upregulation of NO synthase expression following exposure of endothelial cells to exogenous NO. 15 In summary, this study provides evidence of no increased morbidity from withdrawing inhaled NO from patients who do not respond. Nonresponders in this study had no acute deterioration in oxygenation 30 minutes after discontinuing NO.
Furthermore, general guidelines for the usage of NO can include a trial of 30 minutes and safe cessation of therapy from treatment failures. At our institution, we routinely discontinue NO if there is no response (greater than 10 torr increase in PaO 2 ) on 20 to 40 ppm after 15 minutes. It is our opinion that NO may be safely administered for a short trial period and then withdrawn if there is no response.
